Bioavailability/Bioequivalence on Biopharmaceutical Products
The Bioavailability Bioequivalence Research Center aims to become a regional center of excellence for assuring the safety and efficacy of generic pharmaceutical products for human use. It plays a key role in the drug development period for both new drug products and their generic equivalents. These studies are also important in the post approval period in the presence of certain manufacturing changes. Information in the overall set of data that ensure the availability of safe and effective medicines to patients and practitioners can be discussed
- Factors affecting bae
- BABE studies
- Assesssment of bioeqivalence
- In vivo/In vitro studies
- Latest Updates In BA/BE
Related Conference of Bioavailability/Bioequivalence on Biopharmaceutical Products
June 27-28, 2018
4thInternational Conference on Drug Discovery, Designing Chemistry and Pharmaceutical Analysis
Vancouver, British Columbia, Canada
August 29-30, 2018 |
International Conference and Exhibition on Drug Safety & Pharmacovigilance
Park Inn By Radisson, Toronto, Canada
Bioavailability/Bioequivalence on Biopharmaceutical Products Conference Speakers
Recommended Sessions
- Bioavailability/Bioequivalence on Biopharmaceutical Products
- Biologics and Biosimilars
- Biopharmaceutical Companies & Market Analysis
- Biopharmaceutical Pharmacovigilance
- Biopharmaceuticals
- Biopharmaceutics: Drug Discovery and Development
- Biotechnological Products
- Cellular and Gene Therapy
- clinical Trials on Biopharmaceutical Products
- Drug Delivery System of Biopharmaceutical Products
- Drug Disposition & Pharmacokinetics
- Drug Dissolution of Biopharmaceutical Products
- Entrepreneurs Investment Meet
- Pharmaceutical Regulatory Affairs And IPR
- Pharmacovigilance
- Therapeutic Biological Products
Related Journals
Are you interested in
- Adverse Drug Reactions - Drug Safety 2018 (UK)
- Analytical Strategies for Biosimilars - Biosimilar Congress 2018 (Portugal)
- Anesthesia in Pain Treatment - Pain Medicine 2018 (USA)
- Array of clinical trials in biosimilars - Generic Biosimilars 2018 (Germany)
- BCS & IVIVC Based Biowaivers - Biosimilar Congress 2018 (Portugal)
- BCS & IVIVC Based Biowaivers - Asian Biosimilars 2018 (Japan)
- Bio-Pharmaceutics - Pharma Congress 2018 (Poland)
- Bioavailability/Bioequivalence on Biopharmaceutical Products - Euro Biopharma 2018 (Netherlands)
- Bioequivalence Assessment - Asian Biosimilars 2018 (Japan)
- Biological Medicines - Biosimilar Congress 2018 (Portugal)
- Biologics & Biosimilars - Pharma Congress 2018 (Poland)
- Biologics and Biosimilars - Euro Biopharma 2018 (Netherlands)
- Biopharmaceutical - Biosimilar Congress 2018 (Portugal)
- Biopharmaceutical Companies & Market Analysis - Euro Biopharma 2018 (Netherlands)
- Biopharmaceutical Pharmacovigilance - Euro Biopharma 2018 (Netherlands)
- Biopharmaceutical Sciences - Drug Safety 2018 (UK)
- Biopharmaceuticals - Euro Biopharma 2018 (Netherlands)
- Biopharmaceutics: Drug Discovery and Development - Euro Biopharma 2018 (Netherlands)
- Biosimilar and biologics - Generic Biosimilars 2018 (Germany)
- Biosimilar Companies and Market Analysis - Asian Biosimilars 2018 (Japan)
- Biosimilar development challenges - Generic Biosimilars 2018 (Germany)
- Biosimilar Gonadotropins - Biosimilar Congress 2018 (Portugal)
- Biosimilar Market and Cost Analysis - Asian Biosimilars 2018 (Japan)
- Biosimilar Market and Cost Analysis - Biosimilar Congress 2018 (Portugal)
- Biosimilars Analytical Strategies - Asian Biosimilars 2018 (Japan)
- Biosimilars and Biologic growth in Markets - Biosimilar Congress 2018 (Portugal)
- Biosimilars differentiated through novel drug delivery technologies - Generic Biosimilars 2018 (Germany)
- Biosimilars Research Pipeline - Biosimilar Congress 2018 (Portugal)
- Biosimilars Research Pipeline - Asian Biosimilars 2018 (Japan)
- Biosimilars uptake and patient safety - Generic Biosimilars 2018 (Germany)
- Biosimilars- Legal Issues and BPCI Act - Biosimilar Congress 2018 (Portugal)
- Biotechnological Products - Euro Biopharma 2018 (Netherlands)
- Brexit Effect on Biosimilars - Asian Biosimilars 2018 (Japan)
- Cardiovascular Drug Discovery - Drug Designing 2018 (Canada)
- Case study mitigating risk in biosimilar development - Generic Biosimilars 2018 (Germany)
- Cellular and Gene Therapy - Euro Biopharma 2018 (Netherlands)
- Challenges in Developing Biosimilars - Asian Biosimilars 2018 (Japan)
- Chronicles of biosimilar production facility - Generic Biosimilars 2018 (Germany)
- Clinical and Hospital Pharmacy - Pharma Congress 2018 (Poland)
- Clinical Data Management and Analytics - Drug Safety 2018 (UK)
- Clinical Database Management - Drug Safety 2018 (UK)
- Clinical Development of Biosimilars - Biosimilar Congress 2018 (Portugal)
- Clinical Research and Statistics - Drug Safety 2018 (UK)
- Clinical Studies on Biosimilars - Asian Biosimilars 2018 (Japan)
- Clinical Trial Protocols - Drug Safety 2018 (UK)
- Clinical Trial Site Selection and Management - Drug Safety 2018 (UK)
- Clinical Trials and Clinical Research - Pharma Congress 2018 (Poland)
- Clinical Trials and Regulatory Affairs - Drug Designing 2018 (Canada)
- clinical Trials on Biopharmaceutical Products - Euro Biopharma 2018 (Netherlands)
- Computational Molecular Biology - Drug Designing 2018 (Canada)
- Computer Aided Drug Design (CADD) - Drug Designing 2018 (Canada)
- Developing biosimilars and biobetters - Generic Biosimilars 2018 (Germany)
- Diversity in Industrial Clinical Trials and Clinical Research - Drug Safety 2018 (UK)
- Drug Delivery and Development - Biosimilar Congress 2018 (Portugal)
- Drug Delivery and Targeting - Drug Designing 2018 (Canada)
- Drug Delivery System of Biopharmaceutical Products - Euro Biopharma 2018 (Netherlands)
- Drug Designing and Molecular Modelling - Drug Designing 2018 (Canada)
- Drug Discovery and Development - Drug Designing 2018 (Canada)
- Drug Discovery in Preclinical Research - Drug Designing 2018 (Canada)
- Drug Disposition & Pharmacokinetics - Euro Biopharma 2018 (Netherlands)
- Drug Dissolution of Biopharmaceutical Products - Euro Biopharma 2018 (Netherlands)
- Drug Safety - Drug Safety 2018 (UK)
- Drug Targeting and Design - Pharma Congress 2018 (Poland)
- Drugs Regulations - Drug Safety 2018 (UK)
- Emerging Biosimilars in Therapeutics - Asian Biosimilars 2018 (Japan)
- Emerging Biosimilars in Therapeutics - Biosimilar Congress 2018 (Portugal)
- Emerging Trends in Biosimilars - Asian Biosimilars 2018 (Japan)
- Entrepreneurs investment meet - Generic Biosimilars 2018 (Germany)
- Entrepreneurs Investment Meet - Asian Biosimilars 2018 (Japan)
- Entrepreneurs Investment Meet - Euro Biopharma 2018 (Netherlands)
- Generic drugs, generic pills and generic medication - Generic Biosimilars 2018 (Germany)
- Generics and biosimilars industry strategy - Generic Biosimilars 2018 (Germany)
- Global generic trends and global pharma market - Generic Biosimilars 2018 (Germany)
- Globalization of Biosimilars - Biosimilar Congress 2018 (Portugal)
- Globalization of Biosimilars - Asian Biosimilars 2018 (Japan)
- GMP, GCP and quality control - Generic Biosimilars 2018 (Germany)
- Good Pharmacovigilance Practice - Drug Safety 2018 (UK)
- Hospital and Indutrial Pharmacy - Drug Safety 2018 (UK)
- Hybridoma technology for production of monoclonal antibodies - Biosimilar Congress 2018 (Portugal)
- Industrial and Physical Pharmacy - Pharma Congress 2018 (Poland)
- Innovation and technology for biosimilar development - Generic Biosimilars 2018 (Germany)
- Intellectual Property Rights - Asian Biosimilars 2018 (Japan)
- Intellectual Property Rights - Biosimilar Congress 2018 (Portugal)
- Latest Biosimilars in Asian Scenario - Asian Biosimilars 2018 (Japan)
- Legal Issues and BPCI Act - Asian Biosimilars 2018 (Japan)
- Licensing, manufacturing and health economics - Generic Biosimilars 2018 (Germany)
- Medical and Clinical Case Reports - Drug Safety 2018 (UK)
- Medicinal Chemistry in Modern Drug Discovery - Drug Designing 2018 (Canada)
- Nanomedicine and Biomedical Applications - Pharma Congress 2018 (Poland)
- Nanotechnology in Drug Discovery - Drug Designing 2018 (Canada)
- Natural products Drug Discovery - Drug Designing 2018 (Canada)
- Natural Supplements for Pain Management - Pain Medicine 2018 (USA)
- Novel Drug Delivery Systems - Pharma Congress 2018 (Poland)
- Novel Therapeutics in Drug Designing - Drug Designing 2018 (Canada)
- Office of generic drugs (OGD) - Generic Biosimilars 2018 (Germany)
- Orofacial Pain - Pain Medicine 2018 (USA)
- Pain Management - Pain Medicine 2018 (USA)
- Pain Management Market - Pain Medicine 2018 (USA)
- Pain Management Nursing - Pain Medicine 2018 (USA)
- Pain Management Specialist - Pain Medicine 2018 (USA)
- Pain Medications - Pain Medicine 2018 (USA)
- Pain Medicine - Pain Medicine 2018 (USA)
- Patent access and intellectual property and FDA regulations - Generic Biosimilars 2018 (Germany)
- Pharma pricing and market access - Generic Biosimilars 2018 (Germany)
- Pharmaceutical Analysis - Pharma Congress 2018 (Poland)
- Pharmaceutical and Biomedical Analysis - Drug Designing 2018 (Canada)
- Pharmaceutical Biotechnology - Pharma Congress 2018 (Poland)
- Pharmaceutical Biotechnology and Clinical Drug Evaluation - Drug Designing 2018 (Canada)
- Pharmaceutical Chemistry - Pharma Congress 2018 (Poland)
- Pharmaceutical Formulation - Pharma Congress 2018 (Poland)
- Pharmaceutical Formulation - Drug Designing 2018 (Canada)
- Pharmaceutical Manufacturing - Pharma Congress 2018 (Poland)
- Pharmaceutical Microbiology - Pharma Congress 2018 (Poland)
- Pharmaceutical Nanotechnology - Pharma Congress 2018 (Poland)
- Pharmaceutical Packaging - Pharma Congress 2018 (Poland)
- Pharmaceutical Process Validation - Pharma Congress 2018 (Poland)
- Pharmaceutical Regulatory Affairs And IPR - Euro Biopharma 2018 (Netherlands)
- Pharmaceutical Research and Development - Drug Designing 2018 (Canada)
- Pharmacogenetics and Genomics - Pharma Congress 2018 (Poland)
- Pharmacognosy and Phytochemistry - Pharma Congress 2018 (Poland)
- Pharmacological Sciences - Pharma Congress 2018 (Poland)
- Pharmacology and drug developement - Generic Biosimilars 2018 (Germany)
- Pharmacovigilance - Euro Biopharma 2018 (Netherlands)
- Pharmacovigilance and Drug Safety - Pharma Congress 2018 (Poland)
- Pharmacovigilance and safety of biosimilars - Generic Biosimilars 2018 (Germany)
- Pharmacovigilance of Biosimilars - Biosimilar Congress 2018 (Portugal)
- Pharmacovigilance of Biosimilars - Asian Biosimilars 2018 (Japan)
- Pharmacy Education and Practice - Pharma Congress 2018 (Poland)
- Physical Medicine and Rehabilitation - Pain Medicine 2018 (USA)
- Pre-Clinical and Clinical Trials - Drug Safety 2018 (UK)
- Present Challenges in Developing Biosimilars - Biosimilar Congress 2018 (Portugal)
- Protein biotherapeutics and biosimilars - Generic Biosimilars 2018 (Germany)
- Quality control and R&D - Generic Biosimilars 2018 (Germany)
- Regulatory Affairs and Intellectual Property Rights - Pharma Congress 2018 (Poland)
- Regulatory Approach for Biosimilars - Asian Biosimilars 2018 (Japan)
- Therapeutic Biological Products - Euro Biopharma 2018 (Netherlands)